Zbornik sestanka: Redkejše preobčutljivostne ... - Bolnišnica Golnik

ZAKLJUČEKBiološka zdravila so odprla novo poglavje v zdravljenju vnetnih revmatičnih bolezni.Dosedanji podatki kažejo, da so to učinkovita in ob skrbnem spremljanju bolnikovrazmeroma varna zdravila. Ali je začetno navdušenje upravičeno pa bodo pokazalenadaljnje izkušnje in čas.LITERATURA1) Lee SJ, Kavanaugh A. Adverse reactions to biologic agents: focus on autoimmune disease therapies. J Allergy Clin Immunol2005;116:900-5.2) Haraoui B, Keystone E. Musculoskeletal Manifestations and Autoimmune Diseases Related to New Biologic Agents. CurrOpin Rheumatol 2006;18:96-100.3) Lee SJ, Kavanaugh A. Biologic agents in rheumatology: safety considerations.Rheum Dis Clin North Am 2006;32 Suppl 1:3-10.4) Alessandri C, Scrivo R, Spinelli FR, Ceccarelli F, Magrini L, Priori R, Valesini G. Autoantibody production in anti-TNF-alphatreatedpatients. Ann N Y Acad Sci 2007;1110:319-29.5) Ramos-Casals M, Brito-Zerón P, Muñoz S, Soria N, Galiana D, Bertolaccini L, Cuadrado MJ, Khamashta MA. Autoimmunediseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore) 2007;86:242-51.6) Campi P, Benucci M, Manfredi M, Demoly P. Hypersensitivity reactions to biological agents with special emphasis on tumornecrosis factor-alpha antagonists. Curr Opin Allergy Clin Immunol 2007;7:393-403.7) Consensus statement on the use of rituximab in patients with rheumatoid arthritis.Smolen JS, Keystone EC, Emery P, Breedveld FC, Betteridge N, Burmester GR, Dougados M, Ferraccioli G, Jaeger U,Klareskog L, Kvien TK, Martin-Mola E, Pavelka K; Working Group on the Rituximab Consensus Statement. Ann Rheum Dis2007;66:143-50.27